TORONTO, Aug. 19, 2014 /PRNewswire/ -- Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. It carries out basic drug discovery research and clinical development. Nutra Pharma, through its subsidiary, ReceptoPharm, manufactures over-the counter (OTC) drug products for the treatment of moderate to severe chronic pain named Nyloxin®. It is also engaged in the research and development of novel anticholinergic therapeutic protein products for the treatment of autoimmune and neurologic disorders.
An analyst report which details an overview of the company, financial and competitive analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Houman Farahani, CFA Candidate. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at firstname.lastname@example.org. For any urgent concerns or inquiries please contact us at email@example.com.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.